Number of the records: 1  

Cell-type specific anti-cancerous effects of nitro-oleic acid and its combination with gamma irradiation

  1. 1.
    0583536 - BFÚ 2024 RIV DE eng J - Journal Article
    Perečko, Tomáš - Perečková, Jana - Hoferová, Zuzana - Falk, Martin
    Cell-type specific anti-cancerous effects of nitro-oleic acid and its combination with gamma irradiation.
    Biological Chemistry. Roč. 2023, SEP 15 2023 (2023). ISSN 1431-6730. E-ISSN 1437-4315
    Institutional support: RVO:68081707
    Keywords : conjugated linoleic-acid * fatty-acids * radiation * oxide * radiosensitivity * apoptosis * sensitivity
    OECD category: Biochemistry and molecular biology
    Impact factor: 3.7, year: 2022
    Method of publishing: Limited access
    https://www.degruyter.com/document/doi/10.1515/hsz-2023-0150/html

    Nitro-fatty acids (NFAs) are endogenous lipid mediators capable of post-translational modifications of selected regulatory proteins. Here, we investigated the anti-cancerous effects of nitro-oleic acid (NO(2)OA) and its combination with gamma irradiation on different cancer cell lines. The effects of NO(2)OA on cell death, cell cycle distribution, or expression of p21 and cyclin D1 proteins were analyzed in cancer (A-549, HT-29 and FaDu) or normal cell lines (HGF, HFF-1). Dose enhancement ratio at 50?% survival fraction (DERIC50) was calculated for samples pre-treated with NO(2)OA followed by gamma irradiation. NO(2)OA suppressed viability and induced apoptotic cell death. These effects were cell line specific but not in general selective for cancer cells. HT-29 cell line exerted higher sensitivity toward NO(2)OA treatment among cancer cell lines tested: induction of cell cycle arrest in the G2/M phase was associated with an increase in p21 and a decrease in cyclin D1 expression. Pre-treatment of HT-29 cells with NO(2)OA prior irradiation showed a significantly increased DERIC50, demonstrating radiosensitizing effects. In conclusion, NO(2)OA exhibited potential for combined chemoradiotherapy. Our results encourage the development of new NFAs with improved features for cancer chemoradiation.
    Permanent Link: https://hdl.handle.net/11104/0351550

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.